Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
Key Highlights
- ➤Evommune licenses worldwide rights outside Greater China to develop, manufacture and commercialize EVO570
- ➤Evommune pays $30 million upfront, including $20 million cash and $10 million pre-funded warrants
- ➤Hinova eligible for approximately $1.1 billion in development, regulatory and commercial milestones
- ➤Phase 1 trial expected imminently; Evommune plans rheumatoid arthritis Phase 2 trial in 2027
- ➤EVO570 is an oral VAV1 molecular glue degrader with sub-nanomolar potency and once-daily dosing potential
Expert Statements
Jeegar Patel, Chief Scientific Officer of Evommune
“VAV1 is a compelling target in immunology today, offering a potential path to JAK-like efficacy without the safety and tolerability challenges of other available therapies”
Jeegar Patel, Chief Scientific Officer of Evommune
“With a differentiated scaffold and structure-guided optimization resulting in sub-nanomolar potency, high selectivity and a profile supporting once-daily oral dosing, EVO570 has the potential to be a best-in-class approach for patients with rheumatoid arthritis and other T- and B-cell-driven autoimmune diseases.”
Jeegar Patel, Chief Scientific Officer of Evommune
“We look forward to reporting Phase 1 results and plan to advance it into its first Phase 2 trial in rheumatoid arthritis in 2027.”
Greg Moss, Chief Business and Legal Officer of Evommune
“Adding this development-stage program is a strategic step for Evommune, expanding our pipeline into T- and B-cell-driven autoimmune diseases with a differentiated oral degrader that complements our existing pipeline”
Greg Moss, Chief Business and Legal Officer of Evommune
“We have been impressed by Hinova’s innovative drug discovery and execution capabilities, and we are pleased to partner with a team that shares our commitment to developing differentiated therapies for patients.”
Greg Moss, Chief Business and Legal Officer of Evommune
“With this transaction, we are adding a novel therapeutic candidate with wide-ranging potential, while maintaining a disciplined portfolio management approach, and continuing to position Evommune to create meaningful long-term value for patients with chronic inflammatory diseases and for our stockholders.”
Yuanwei Chen, Founder and Chairman of Hinova
“We are proud to partner with Evommune, a leading immunology company with a proven track record of advancing differentiated therapies for chronic inflammatory diseases”
Yuanwei Chen, Founder and Chairman of Hinova
“EVO570’s advancement reflects the strength of Hinova’s targeted protein degrader and translational medicine platforms, and we believe Evommune’s development expertise and global reach make it the ideal collaborator to bring this potential best-in-class VAV1 degrader to patients worldwide.”
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
- Oral, highly selective and potent VAV1 molecular glue degrader designed to deliver a differentiated clinical profile across a broad range of indications in autoimmune disease
Get started
Create a free account to read the full story.